Literature DB >> 21244914

Molecular atherectomy for restenosis.

W Casscells1, D A Lappi, A Baird.   

Abstract

Receptors for basic (b) and acidic (a) fibroblast growth factor (FGF) are upregulated in activated smooth muscle cells. These cells, which proliferate in response to bFGF, can thus be killed by a conjugate of bFGF and the ribosome-inactivating enzyme, saporin (which, by itself, does not enter the cells). Quiescent smooth muscle cells and other cells that have few FGF receptors are not killed. In vivo, bFGF-saporin transiently inhibits smooth muscle cell proliferation and neointimal accumulation after balloon injury to the rat carotid artery. Delivery of saporin, diagnostic imaging agents, or antisense oligodeoxynucleotides might be made even more selective by linking these substances to antibodies against the extracellular domains of the putative FGF receptor isoform specific for activated smooth muscle cells.
Copyright © 1993. Published by Elsevier Inc.

Entities:  

Year:  1993        PMID: 21244914      PMCID: PMC4524533          DOI: 10.1016/1050-1738(93)90045-8

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  90 in total

Review 1.  Migration of smooth muscle and endothelial cells. Critical events in restenosis.

Authors:  W Casscells
Journal:  Circulation       Date:  1992-09       Impact factor: 29.690

2.  Plaque morphology and pathologic changes in arteries from patients dying after coronary balloon angioplasty.

Authors:  A Farb; R Virmani; J B Atkinson; F D Kolodgie
Journal:  J Am Coll Cardiol       Date:  1990-11       Impact factor: 24.094

Review 3.  Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a "magic bullet".

Authors:  W R Hermans; B J Rensing; B H Strauss; P W Serruys
Journal:  Am Heart J       Date:  1991-07       Impact factor: 4.749

4.  Derivation and properties of platelet-derived growth factor-independent rat smooth muscle cells.

Authors:  S M Schwartz; L Foy; D F Bowen-Pope; R Ross
Journal:  Am J Pathol       Date:  1990-06       Impact factor: 4.307

5.  Culture-induced increase in acidic and basic fibroblast growth factor activities and their association with the nuclei of vascular endothelial and smooth muscle cells.

Authors:  E Speir; J Sasse; S Shrivastav; W Casscells
Journal:  J Cell Physiol       Date:  1991-05       Impact factor: 6.384

6.  Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF.

Authors:  G A Ferns; E W Raines; K H Sprugel; A S Motani; M A Reidy; R Ross
Journal:  Science       Date:  1991-09-06       Impact factor: 47.728

7.  Nuclear and cytoplasmic localization of different basic fibroblast growth factor species.

Authors:  M Renko; N Quarto; T Morimoto; D B Rifkin
Journal:  J Cell Physiol       Date:  1990-07       Impact factor: 6.384

Review 8.  Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies.

Authors:  H F Dvorak; J A Nagy; A M Dvorak
Journal:  Cancer Cells       Date:  1991-03

9.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.

Authors:  A Yayon; M Klagsbrun; J D Esko; P Leder; D M Ornitz
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

10.  Basic fibroblast growth factor in Dupuytren's contracture.

Authors:  A M Gonzalez; M Buscaglia; R Fox; A Isacchi; P Sarmientos; J Farris; M Ong; D Martineau; D A Lappi; A Baird
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.